MS Phase 2 Study Nerispirdine (HP184) Report for Patients Like You

Filter by:

All
Start typing to see suggestions

patients

Home > Community Treatment Reports and Side Effects > MS Phase 2 Study Nerispirdine (HP184) Treatment Report

You appear to have JavaScript disabled in your browser. PatientsLikeMe relies on JavaScript and Cookies to deliver the best possible experience to you. How do I enable JavaScript?

What is MS Phase 2 Study Nerispirdine (HP184)?

NCT00772525 is a double-blind, placebo-controlled, randomized crossover, activity study of single oral doses of 50 mg and 400 mg nerispirdine (HP184) on visual function in patients with multiple sclerosis. Other study name is ACT10573. This is a completed study.

0 patients have reported taking MS Phase 2 Study Nerispirdine (HP184) .

Report created on May 27, 2012.